Therapy of visceral leishmaniasis due to Leishmania infantum: Experimental assessment of efficacy of AmBisome

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 5, 1996, Pages 1214-1218

  Gangneux, Jean Pierre ^a   Sulahian, Annie ^a   Garin, Yves Jean Francois ^a   Farinotti, Robert ^b,c   Derouin, Francis ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b BICHAT HOSPITAL   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; MEGLUMINE ANTIMONATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL COLONIZATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERANCE; FEMALE; LEISHMANIA DONOVANI; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMASTIGOTE; VISCERAL LEISHMANIASIS;

EID: 0029868129     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.5.1214     Document Type: Article

References (31)

1. Adler-Moore, J. 1994. AmBisome targeting to fungal infections. Bone Marrow Transplant. 14(Suppl. 5):S3-S7
2. Alvar, J. 1992 Prevalence of Leishmania infection among AIDS patients. Lancet 339:1427.
3. Berman, J. D., G. Ksionski, W. L. Chapman, V. B. Waits, and W. L. Hanson. 1992 Activity of amphotericin B cholesterol dispersion (Amphocil) in experimental visceral leishmaniasis. Antimicrob. Agents Chemother. 36:1978-1980.
4. Bryceson, A. D. M. 1987. Therapy in man, p. 847-907. In W Peters and R. Killick-Kendrick (ed.), The leishmaniases in biology and medicine, vol. 2. Clinical aspects and control. Academic Press, London.
5. Buffet, P. A., A. Sulahian, Y. J. F. Garin, N. Nassar, and F. Derouin. 1995. Culture microtitration: a sensitive method for quantifying Leishmania infantum in tissues of infected mice. Antimicrob. Agents Chemother. 39:2167-2168.
6. Collins, M., K. C. Carter, and A. J. Baillie. 1992. Visceral leishmaniasis in the Balb/c mouse antimony tissue disposition and parasite suppression after the administration of free stibogluconate. Ann. Trop. Med. Parasitol. 86:35-40.
7. Croft, S. L., R. N. Davidson, and E. A. Thornton. 1991. Liposomal amphotericin B in the treatment of visceral leishmaniasis. J. Antimicrob Chemother 28(Suppl. B):S111-S118.
8. Davidson, R. N., S. Croft, A. Scott, M. Maini, A. H. Moody, and A. D. M. Bryceson. 1991. Liposomal amphotericin B in drug-resistant visceral leishmaniasis. Lancet 337:1061-1062.
9. Davidson, R. N., L. Di Martino, L. Gradoni. R. Giacchino, R. Russo, G. B. Gaeta, R. Pempinello, S. Scott, F. Raimondi, A. Cascio, T. Prestileo, L. Caldeira, R. J. Wilkinson, and A. D. M. Bryceson. 1994. Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multicentre trial. Q. J Med. 87:75-81.
10. Davidson, R. N., and R. Russo. 1994. Relapse of visceral leishmaniasis in patients who were coinfected with human immunodeficiency virus and who received treatment with liposomal amphotericin B. Clin. Infect. Dis. 19:560
11. Dereure, J., J. Reynes, F. Pratlong, I. Lamaury, J. A. Rioux, F. Janbon, and J. P. Dedet. 1995. Visceral leishmaniasis in HIV-infected patients in the south of France. Bull. W. H. O. 73:245-246.
12. Dietze, R., S. M. S. Fagundes, E. F. Brito, E. P. Milan, T. F. Feilosa, F. A. B. Suassuna, G. Fonschiffrey, G. Ksionski, and J. Dember. 1995. Treatment of kala-azar in Brazil with Amphocil (amphotericin B cholesterol dispersion) for 5 days. Trans. R. Soc. Trop. Med Hyg 89:309-311.
13. Dupla, M. L., A. G. Aguado, P. L. Uriol, V. P. Garcia, E. V. Ortega, P. M. Martinez, and J. Garcia-Puig. 1993. Efficacy of liposomal amphotericin B in the treatment and secondary prophylaxis of visceral leishmaniasis in HIV infected patients: report of two cases. J. Antimicrob Chemother. 32:657-659, (Letter.)
14. 13a.Gangneux, J.-P., A. Sulahian, Y. J.-F. Garin, and F. Derouin. Lipid formulations of amphotericin B (AmB) in the treatment of experimental visceral leishmaniasis (VL). abstr B58, p 36. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
15. Gradoni, L., A. Bryceson, and P. Desjeux. 1995. Treatment of mediterranean visceral leishmaniasis. Bull. W. H. O. 73:191-197.
16. Gradoni, L., R. N. Davidson, S. Orsini, P. Betto, and M. Giambenedetti. 1993. Activity of liposomal amphotericin B (AmBisome) against Leishmania infantum and tissue distribution in mice. J. Drug Target. 1:311-316.
17. Heinemann, V., B. Kahny, A. Debus, K. Wachholz, and U. Jehn. 1994. Pharmacokinetics of liposomal amphotericin B (AmBisome) versus other lipid-based formulations. Bone Marrow Transplant. 14:58-59.
18. Janknegt, R., S. de Marie, I. A. J. M. Bakker-Woudenberg, and D. J. A. Crommelin. 1992. Liposomal and lipid formulations of amphotericin B. Clin Pharmacokinet. 23:279-291.
19. Khoo, S. H., J. Bond, and D. W. Denning. 1994. Administering amphotericin B - a practical approach J Antimicrob. Chemother. 33:203-213
20. Lazanas, M. C., G. A. Tsekes, S. Papandreou, N. Harhalakis, A. Scandall, E. Nikiforakis, and G. Saroglou. 1993 Liposomal amphotericin B for leishmaniasis treatment of AIDS patients unresponsive to antimonium compounds. AIDS 7:1019.
21. Mishra, M., U. K. Biswas, A. M. Jha, and A. B. Khan. 1994. Amphotericin versus sodium stibogluconatc in first-line treatment of Indian kala-azar. Lancet 344:1599-1600.
22. Montalban, C., J. L. Calleja, A. Erice, F. Laguna, B. Clotet, D. Podzamczer, J. Cobbo, J. Mallolas, M. Yebra, A. Gallego, and the Co-operative Group for the Study of Leishmaniasis in AIDS. 1990 Visceral leishmaniasis in patients infected with human immunodeficiency virus. J. Infect 21:261-270.
23. Montalban, C., F. Sevilla, A. Moreno, R. Nash, M. L. Celma, and R. F. Munoz. 1987 Visceral leishmaniasis as an opportunistic infection in the acquired immunodeficiency syndrome J. Infect 15:247-250.
24. New, R. R. C. 1981. Antileishmanial activity of amphotericin and other antifungal agents entrapped in liposomes. J. Antimicrob. Chemother. 8:371-381.
25. Panosian, C. B., M. Barza, F. Szoka, and D. J. Wyler. 1984. Treatment of experimental cutaneous leishmaniasts with liposome-intercalated amphotericin B. Antimicrob. Agents Chemother. 25:655-656.
26. Rosenthal, E., P. Marty, I. Poizot-Martin, J. Reynes, F. Pratlong, A. Lafeuillade, D. Jauhert, O. Boulat, J. Dereure, F. Gambarelli, J. A. Gastaut, P. Dujardin, P. Dellamonica, and J. P. Cassuto. 1995 Visceral leishmaniasis and HIV-1 co-infection in southern France. Trans. R. Soc. Trop. Med. Hyg. 89:159-162.
27. Seaman, J., B. Coby, R. Wilkinson, J. de Jong, E. de Wilde, E. Sondorp, and R. Davidson. 1995. Liposomal amphotericin B (AmBisome) in the treatment of complicated kala-azar undei field conditions. Clin. Infect. Dis. 21:188-193.
28. Sundar, S., and H. W. Murray. Cure of antimony-unresponsive Indian visceral leishmaniasis with liposomal amphotericin B lipid complex. J. Infect. Dis , in press.
29. Thakur, C. P., G. P. Sinha, D. Barat, and R. K. Singh. 1994 Are incremental doses of amphotericin B required for the treatment of visceral leishmaniasis? Ann. Trop Med. Parasitol. 88:365-370.
30. Tollemar, J., S. Andersson, O. Ringden, and G. Tyden. 1992. A retrospective clinical comparison between antifungal treatment with liposomal amphotericin B (AmBisome) and conventional amphotericin B in transplant recipients. Mycoses 35:215-220
31. Torre-Cisneros, J., J. L. Villanueva, J. M. Kindelan, R. Jurado, and P. Sanchez-Guijo. 1993. Successful treatment of antimony-resistant visceral leishmaniasis with liposomal amphotericin B in patients infected with human immunodeficiency virus. Clin Infect. Dis. 17:625-627.